Pre-made Melrilimab benchmark antibody ( Whole mAb, anti-IL1RL1/ST2 therapeutic antibody, Anti-DER4/FIT-1/IL33R/T1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-340
Pre-Made Melrilimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Melrilimab (formerly GSK 3772847) was a monoclonal antibody targeting interleukin-1 receptor-like 1 (IL1RL1 or ST2 or IL-33R), which was being developed by GlaxoSmithKline for the treatment of asthma and atopic dermatitis. Clinical development was ongoing in the US and the UK.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Melrilimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Asthma;Atopic dermatitis|